Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Disorders of Hemostasis01:24

Disorders of Hemostasis

906
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
906
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
Coagulation01:09

Coagulation

6.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Introduction to Hemostasis01:05

Introduction to Hemostasis

7.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor.

Blood·2025
Same author

Thrombophilic thrombomodulin variants.

Blood·2025
Same author

The Change in Liver Volume After Inferior Vena Cava and/or Hepatic Vein Venoplasty in Patients With Budd Chiari Syndrome With at Least One Patent Hepatic Vein Presenting With Ascites.

Journal of clinical and experimental hepatology·2025
Same author

Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel <i>FGG</i> mutation.

Frontiers in cardiovascular medicine·2024
Same author

Plasma levels of complement components C5 and C9 are associated with thrombin generation.

Journal of thrombosis and haemostasis : JTH·2024
Same author

In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency.

Journal of thrombosis and haemostasis : JTH·2023

相关实验视频

Updated: Jul 2, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K

在出血和血栓形成中的V因子变异.

Adarsh K Mohapatra1, Alice M Todaro1, Elisabetta Castoldi1

  • 1Department of Biochemistry, CARIM, Maastricht University, Maastricht, the Netherlands.

Research and practice in thrombosis and haemostasis
|February 26, 2024
PubMed
概括

因素V (FV) 变异影响静血平衡,影响出血和血栓形成的风险. 在F5基因的突变可以改变FV.

科学领域:

  • 血液学 血液学 血液学
  • 分子生物学分子生物学
  • 遗传学 是一个遗传学.

背景情况:

  • 血液凝固是一系列复杂的过程,涉及酶反应.
  • 因素V (FV) 是至关重要的,作为一种促凝剂和抗凝剂的辅因子.
  • 静脉功能失衡与出血障碍和静脉血栓症有关.

研究的目的:

  • 审查V因子的促凝和抗凝作用.
  • 探索F5基因突变如何影响静血平衡.
  • 讨论与FV功能障碍相关的病理状况.

主要方法:

  • 关于因子V的科学文献的综述.
  • 分析F5基因突变及其功能后果.
  • 讨论病理状况,包括FV缺乏,APC耐药性和FV短.

主要成果:

  • 维因子在凝血中表现出双重作用,对血栓生成和凝血调节至关重要.
  • F5基因突变会破坏促凝剂/抗凝剂平衡,导致出血或血栓形成.
  • FV缺陷,APC耐药性和FV短过度表达是关键的病理状态.

结论:

关键词:
在FV-short中,使用FV-short.流血 出血 流血 出血这就是V因子V因子.突变是一种突变.静脉血栓的形成 静脉血栓的形成

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.8K

相关实验视频

Last Updated: Jul 2, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.8K
  • 维因子是血液静止的中央调节剂.
  • 了解F5基因变异对于诊断和管理出血和血栓性疾病至关重要.
  • 像FV-short这样的FV异型的新兴角色需要进一步的研究.